Sign in
Taking peoplePhase 4

Tocilizumab with or without flupentixol-melitracen for thyroid eye disease

Tests adding flupentixol-melitracen to tocilizumab in adults with thyroid-associated ophthalmopathy.

Key facts

Who runs it
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
Status
Recruiting
Phase
Phase 4
People taking part
60 people, planned
Started
12 Dec 2024
Planned end
12 Mar 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)
  • Tocilizumab(400mg)
Record updated
16 April 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Aged between 18 and 80 years (inclusive)
  • Meets internationally recognized diagnostic criteria for TED with the more severely affected eye in moderate to severe active phase. Meeting any one of the following criteria qualifies as moderate to severe: an exophthalmos ≥2 mm compared with normal values for sex and race; presence of inconstant to constant diplopia; a lid retraction ≥2 mm. A Clinical Activity Score (CAS) of ≥3 or a score of 2 combined with MRI evidence indicating active disease is defined as active
  • Normal thyroid function within one month prior to enrollment: including those currently taking antithyroid drugs or not requiring medication, with FT3 and FT4 levels within normal range and TSH either normal or decreased
  • HAMA (Hamilton Anxiety Rating Scale) score of ≥14
  • Voluntary participation and provision of informed consent

Who cannot take part

  • Received radioactive iodine treatment or hepatitis vaccination within three months prior to enrollment
  • Received systemic immunotherapy for TAO, including oral or intravenous glucocorticoids, other immunosuppressants, or orbital radiotherapy within one month prior to enrollment
  • communicable disease
  • Severe mental disorders that affect compliance
  • Presence of other clinically significant or unstable systemic diseases
  • Severe cardiac, hepatic, or renal insufficiency (including myocardial ischemia or myocardial infarction, arrhythmias, and heart failure; ALT, AST ≥ 3 times the upper limit of normal; eGFR < 60 ml/min/1.73 m²)
  • Pregnancy or planning to become pregnant
  • Currently breastfeeding
  • Planning to undergo other treatments during the course of this study
  • Patients who are unlikely to complete the entire course of treatment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity. The activity of TAO is commonly evaluated using the Clinical Activity Score (CAS). Tocilizumab serves as a second-line treatment option for patients with moderate to severe active TAO. Additionally, it is common for TAO patients to experience anxiety, which may exacerbate their condition and negatively impact prognosis. Therefore, we have designed this randomized controlled study to evaluate the impact of Flupentixol Melitracen (Lepan) on the treatment outcomes of participants receiving Tocilizumab (Actemra).

The 2 groups in the trial

  • Tocilizumab combined with Flupentixol MelitracenTreatment being tested

    Treatment: Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)

  • TocilizumabExisting treatment, for comparison

    Treatment: Tocilizumab(400mg)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy: A Prospective Exploratory Study
Plain-language title
Tocilizumab with or without flupentixol-melitracen for thyroid eye diseaseGenerated from the registry record. The registry title is the official one.
Fit questions
Built from NCT06927375, who can take part
Record updated
16 April 2025